Pulmonary Fibrosis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, canbiopharm

Pulmonary Fibrosis Pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analyzes DelveInsight.

Pulmonary Fibrosis Overview:

Pulmonary fibrosis (PF) is a chronic, progressive lung disorder marked by excessive buildup of extracellular matrix (ECM) and structural remodeling of the lungs. This process causes tissue scarring and thickening, which hinders efficient gas exchange and leads to a steady decline in respiratory function. Clinically, the disease manifests with symptoms such as persistent shortness of breath, chronic cough, and fatigue, while imaging studies typically reveal hallmark patterns of interstitial fibrosis.

The development of PF is driven by a combination of genetic predisposition, environmental exposures, and abnormal cellular responses. A central aspect of its pathology is the disruption of normal wound-healing mechanisms. Under typical conditions, lung injury triggers a repair cascade involving inflammation, epithelial regeneration, and controlled collagen deposition. In PF, however, this process becomes dysregulated, transforming into persistent fibrosis rather than proper tissue repair. This imbalance between pro-fibrotic and anti-fibrotic signaling-most notably involving the transforming growth factor-beta (TGF-β) pathway-results in continuous fibroblast activation and excessive collagen production, ultimately causing progressive scarring within the lung interstitium.

Request for a detailed insights report on Pulmonary Fibrosis pipeline insights https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Pulmonary Fibrosis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Fibrosis Therapeutics Market.

Key Takeaways from the Pulmonary Fibrosis Pipeline Report

DelveInsight's Pulmonary Fibrosis pipeline report depicts a robust space with 110+ active players working to develop 140+ pipeline therapies for Pulmonary Fibrosis treatment.
The FDA has granted Orphan Drug Designation to taladegib, an investigational Hedgehog signaling inhibitor being explored for idiopathic pulmonary fibrosis (IPF). In a Phase 2a trial, taladegib showed promising improvements in lung volume and pulmonary vessel volume using advanced imaging biomarkers. A Phase 2b trial (WHISTLE-PF) is underway and expected to complete enrollment by 2026.
In January 2025, the FDA awarded Fast Track designation to buloxibutid, an oral drug in development for IPF. This designation is intended to expedite its review process.
Key Pulmonary Fibrosis companies such as Bristol-Myers Squibb, PureTech Health, Sarepta Therapeutics, Boehringer Ingelheim, Avalyn Pharma, SRN-001, Wuhan Optics Valley, canbiopharma Co., Ltd., Syndax Pharmaceuticals, Endeavor BioMedicines, AstraZeneca, Pulmongene Ltd., Agomab Therapeutics, and others are evaluating new drugs for Pulmonary Fibrosis to improve the treatment landscape.
Promising Pulmonary Fibrosis pipeline therapies in various stages of development include BMS-986278, LYT-100, AP01, ARO-MMP7, VUM02, and others.

Pulmonary Fibrosis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Fibrosis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Fibrosis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Fibrosis market.

Download our free sample page report on Pulmonary Fibrosis pipeline insights https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pulmonary Fibrosis Emerging Drugs

BMS-986278 - Bristol Myers Squibb

BMS-986278 is an oral, small-molecule lysophosphatidic acid receptor 1 (LPA1) antagonist being investigated as a novel antifibrotic therapy for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis. Elevated LPA levels and LPA activation play a critical role in fibrosis development. BMS-986278 acts as a potent, full antagonist of LPA1, blocking signaling through Gi, Gq, G12, and β-arrestin pathways in both engineered human LPA1-expressing cells and primary human lung fibroblasts. The therapy is currently in Phase III clinical trials for pulmonary fibrosis.
LYT-100 - PureTech Health

LYT-100 (deupirfenidone) is in development for idiopathic pulmonary fibrosis (IPF), a rare, progressive, and life-threatening lung disease. It is a deuterated derivative of pirfenidone, designed to preserve the proven pharmacological effects and clinical efficacy of pirfenidone while offering an improved pharmacokinetic (PK) profile. Clinical studies have shown that LYT-100 demonstrates enhanced tolerability, potentially enabling longer treatment duration and better disease management. The drug is currently being evaluated in Phase II clinical trials for pulmonary fibrosis.

Pulmonary Fibrosis Companies

There are over 110 companies actively developing therapies for pulmonary fibrosis. Among them, Bristol-Myers Squibb has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 75+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Request the Sample PDF to Get Detailed Insights About the Pulmonary Fibrosis Pipeline Reports Offerings https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Pulmonary Fibrosis Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pulmonary Fibrosis Therapies and Key Companies: Pulmonary Fibrosis Clinical Trials and advancements https://www.delveinsight.com/report-store/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pulmonary Fibrosis Pipeline Therapeutic Assessment
• Pulmonary Fibrosis Assessment by Product Type
• Pulmonary Fibrosis By Stage
• Pulmonary Fibrosis Assessment by Route of Administration
• Pulmonary Fibrosis Assessment by Molecule Type

Download Pulmonary Fibrosis Sample report to know in detail about the Pulmonary Fibrosis treatment market @ Pulmonary Fibrosis Therapeutic Assessment https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.